{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:19:55Z","timestamp":1773865195777,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The RCC treatment landscape has evolved dramatically over the past decade. The purpose of this study is to present a real-world data estimation of RCC\u2019s cost-of-illness for this tumour\u2019s clinical pathway.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This investigation is a population-based cohort study using real-world data, which considers all RCC incident cases diagnosed in Local Unit 6 of the Province of Padua in 2016 and 2017 as registered by the Veneto Cancer Registry. Data on drug prescriptions, the use of medical devices, hospital admissions, and visits to outpatient clinics and emergency departments were collected by means of administrative databases. We evaluated the costs of all healthcare procedures performed in the 2\u00a0years of follow-up post-RCC diagnosis. The overall and annual average real-world costs per patient, both as a whole and by single item, were calculated and stratified by stage of disease at diagnosis.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The analysis involved a population of 148 patients with a median age of 65.8\u00a0years, 66.22% of whom were male. Two years after diagnosis, the average total costs amounted to \u20ac21,429 per patient. There is a steady increment in costs with increasing stage at diagnosis, with a total amount of \u20ac41,494 spent 2\u00a0years after diagnosis for stage IV patients, which is 2.44 times higher than the expenditure for stage I patients (\u20ac17,037). In the first year, hospitalization appeared to be the most expensive item for both early and advanced disease. In the second year, however, outpatient procedures were the main cost driver in the earlier stages, whereas anticancer drugs accounted for the highest costs in the advanced stages.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This observational study provides real-world and valuable estimates of RCC\u2019s cost-of-illness, which could enable policymakers to construct dynamic economic cost-effectiveness evaluation models based on real world costs\u2019 evaluation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12894-022-01160-y","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T20:22:43Z","timestamp":1671481363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Renal cell carcinoma: the population, real world, and cost-of-illness"],"prefix":"10.1186","volume":"22","author":[{"given":"Alessandra","family":"Buja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maura","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Cozzolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Rugge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Zorzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Gardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Sepulcri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Bimbatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Baldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Maruzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Basso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorina","family":"Zagonel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"key":"1160_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"1160_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.14740\/wjon1279","volume":"11","author":"SA Padala","year":"2020","unstructured":"Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020;11:79\u201387.","journal-title":"World J Oncol"},{"key":"1160_CR3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1160_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0300891619839844","volume":"105","author":"C Buzzoni","year":"2019","unstructured":"Buzzoni C, Crocetti E, Guzzinati S, et al. Cancer incidence and mortality trends from 2003 to 2014 in Italy. Tumori. 2019;105:121\u201337.","journal-title":"Tumori"},{"key":"1160_CR5","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.eururo.2019.02.011","volume":"75","author":"B Ljungberg","year":"2019","unstructured":"Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol. 2019;75:799\u2013810.","journal-title":"Eur Urol"},{"key":"1160_CR6","unstructured":"Portale Sanit\u00e0 Regione del Veneto\u2014PDTA Rene. Available at https:\/\/salute.regione.veneto.it\/web\/rov\/pdta-rene. Accessed 24 Nov 2022."},{"key":"1160_CR7","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1634\/theoncologist.2017-0481","volume":"23","author":"DR Kaye","year":"2018","unstructured":"Kaye DR, Min HS, Herrel LA, et al. Costs of cancer care across the disease continuum. Oncologist. 2018;23:798\u2013805.","journal-title":"Oncologist"},{"key":"1160_CR8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.euf.2017.03.010","volume":"4","author":"C Camp","year":"2018","unstructured":"Camp C, O\u2019Hara J, Hughes D, et al. Short-term outcomes and costs following partial nephrectomy in England: a population-based study. Eur Urol Focus. 2018;4:579\u201385.","journal-title":"Eur Urol Focus"},{"key":"1160_CR9","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/iju.12446","volume":"21","author":"T Takagi","year":"2014","unstructured":"Takagi T, Sugihara T, Yasunaga H, et al. Cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based analysis of perioperative outcomes according to clinical stage. Int J Urol. 2014;21:770\u20135.","journal-title":"Int J Urol"},{"key":"1160_CR10","doi-asserted-by":"publisher","first-page":"A727","DOI":"10.1016\/j.jval.2016.09.2177","volume":"19","author":"S Nazha","year":"2016","unstructured":"Nazha S, Prevost N, Tanguay S, et al. Economic evaluation of targeted therapies in metastatic clear renal cell carcinoma in Canada. Value Health. 2016;19:A727.","journal-title":"Value Health"},{"key":"1160_CR11","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1080\/03007995.2017.1360850","volume":"33","author":"R Maroun","year":"2017","unstructured":"Maroun R, Fleury L, Nachbaur G, et al. Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database. Curr Med Res Opin. 2017;33:1755\u201362.","journal-title":"Curr Med Res Opin"},{"key":"1160_CR12","doi-asserted-by":"publisher","first-page":"e227","DOI":"10.1016\/j.clgc.2018.10.016","volume":"17","author":"T Cholley","year":"2019","unstructured":"Cholley T, Thiery-Vuillemin A, Limat S, et al. Economic burden of metastatic clear-cell renal cell carcinoma for French patients treated with targeted therapies. Clin Genitourin Cancer. 2019;17:e227\u201334.","journal-title":"Clin Genitourin Cancer"},{"key":"1160_CR13","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1159\/000509973","volume":"104","author":"M B\u00f6gemann","year":"2020","unstructured":"B\u00f6gemann M, Zagorska A, Akumo D, et al. Using data from a sickness fund claims database to assess the treatment patterns and healthcare resource utilization among patients with metastatic renal cell carcinoma in Germany. Urol Int. 2020;104:982\u201393.","journal-title":"Urol Int"},{"key":"1160_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/acprof:oso\/9780190492939.001.0001","volume-title":"Cost-effectiveness in health and medicine","year":"2016","unstructured":"Neumann PJ, Ganiats TG, Russell LB, et al editors. Cost-effectiveness in health and medicine. 2nd ed. New York: Oxford University Press; 2016. p. 1\u2013536. https:\/\/doi.org\/10.1093\/acprof:oso\/9780190492939.001.0001.","edition":"2"},{"key":"1160_CR15","unstructured":"Mauskopf J. Cost-consequence analysis. In: Encyclopedia of medical decision making. Thousand Oaks: SAGE Publications Inc; 2009, pp. 209\u201314."},{"key":"1160_CR16","first-page":"1","volume":"16","author":"F Ferre","year":"2014","unstructured":"Ferre F, de Belvis AG, Valerio L, et al. Italy: health system review. Health Syst Transit. 2014;16:1\u2013168.","journal-title":"Health Syst Transit"},{"key":"1160_CR17","unstructured":"LINEE GUIDA AIOM 2016 TUMORI DEL RENE. AIOM. Available at https:\/\/www.aiom.it\/tumori-del-rene-5\/. Accessed 26 Feb 2021."},{"key":"1160_CR18","unstructured":"B. Ljungberg, K. Bensalah, A. Bex et al. European Association of urology guidelines on renal cell carcinoma. 2015. Available at https:\/\/uroweb.org\/guidelines\/archive\/renal-cell-carcinoma. Accessed 24 Nov 2022."},{"key":"1160_CR19","unstructured":"Edition S, Edge SB, Byrd DR. AJCC cancer staging manual. AJCC cancer staging manual 2017."},{"key":"1160_CR20","unstructured":"Regione del Veneto. Nomenclatore tariffario delle prestazioni di assistenza specialistica ambulatoriale. Available at https:\/\/www.regione.veneto.it\/web\/sanita\/assistenza-ambulatoriale. Accessed 24 Nov 2022."},{"key":"1160_CR21","unstructured":"Regione del Veneto. Tariffario DRG Regione del Veneto. Available at https:\/\/salute.regione.veneto.it\/c\/document_library\/get_file?p_l_id=1026082&folderId=1026048&name=DLFE-32750.pdf. Accessed 24 Nov 2022."}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-022-01160-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-022-01160-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-022-01160-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T20:24:07Z","timestamp":1671481447000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-022-01160-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1160"],"URL":"https:\/\/doi.org\/10.1186\/s12894-022-01160-y","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,19]]},"assertion":[{"value":"12 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Istituto Oncologico Veneto\u2014IRCCS on February 17, 2020. All methods were performed in accordance with Cost of Illness study guidelines (Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics. 2011 Aug;29(8):653\u201371).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This is an observational study. The study complied with the Declaration of Helsinki and with the resolution No. 9\/2016 of the Italian Guarantor for the Protection of Personal Data, which also confirmed the permission of processing personal data for medical, biomedical and epidemiological research, and that data concerning people\u2019s health status can be used in aggregate form in scientific studies. To ensure confidentiality and anonymity, the Veneto Regional Authority removes all direct identifiers and replaces them with a code number in all datasets to retain the opportunity to link data from different administrative databases. The data analysis was performed on anonymous aggregated data with no chance of individuals being identifiable. In this case, according to No. 9\/2016 of the Italian Guarantor for the Protection of Personal Data, it is possible to not collect written consent from patients. No minors or illiterate participants were involved in this study. All the procedures were approved by the Ethics Committee of the Istituto Oncologico Veneto\u2014IRCCS on February 17, 2020.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"206"}}